<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00843050</url>
  </required_header>
  <id_info>
    <org_study_id>P276-00/23/08</org_study_id>
    <nct_id>NCT00843050</nct_id>
  </id_info>
  <brief_title>A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma</brief_title>
  <official_title>Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Piramal Enterprises Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Piramal Enterprises Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether P276-00 is safe and effective in treatment
      of Mantle Cell Lymphoma that is recurred after or not responding to at least one previous
      line of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite response rates of up to 97% with first-line standard or high-intensity chemotherapy,
      with or without stem-cell transplantation, most patients of mantle cell lymphoma
      (MCL)relapse.Prognosis of MCL after first relapse is very poor with median survival of around
      1 to 2 years. Therefore, novel therapies are required for relapsed and/or refractory
      MCL.Overexpression of Cyclin D1 as a result of t(11;14)(q13;q32) translocation is the
      hallmark of MCL.It is postulated that Cyclin D1 may also have an oncogenic role independent
      of pRb in MCL.Therefore, inhibition of Cdk4-Cyclin D1 is a potentially promising target in
      MCL. P276-00 is a potent Cdk4-Cyclin D1 inhibitor worth exploring for its efficacy in MCL.
      Hence, this Phase II study is planned to examine the efficacy and safety of P276-00 in the
      treatment of patients with relapsed and/or refractory MCL.

      This is an open-label, single-arm, 2-stage trial. Approximately 35 patients are planned to be
      enrolled into the study to obtain a total of 25 efficacy evaluable patients (patients who
      complete at least 2 cycles of study treatment and have tumor measurements at the end of 2
      cycles). A total of 15 efficacy evaluable patients are planned to be treated in Stage I of
      the study. If ≥1 response (CR or PR) of any duration or ≥2 stable disease (SD) for ≥4 cycles
      are seen in the Stage I, then the study will continue into Stage II, in which additional
      patients will be treated until there are 10 additional efficacy evaluable patients.The study
      is divided into 3 periods: Screening, Treatment, and Follow-up. During the Screening Period,
      patients will provide written informed consent and be evaluated for inclusion and exclusion
      criteria. During the Treatment Period, patients will be administered P276-00 as intravenous
      (iv) infusion on Days 1 to 5 of each 21-day cycle for a minimum of 6 cycles and a maximum of
      12 cycles, or until progressive disease (PD) or unacceptable toxicity occurs. Safety and
      efficacy evaluations will be done on Days 1 to 5 and 11 of each cycle, and on Day 21 of every
      2 cycles. Pharmacokinetic (PK) assessments will be done on Cycle 1, Day 1 (pre-dose and
      post-dose time points), and optional biomarker assessments will be done pre-dose within 4
      weeks of Day 1 and post-dose on Day 4 or 5. The End-of-Last-Cycle Visit will occur at the end
      of Cycle 6, or if the patient continues study treatment beyond Cycle 6, it will occur at the
      end of the patient's last cycle; if the patient discontinues early, these assessments will be
      done as an Early Exit Visit. The Follow-up Visit will occur 4 weeks (±1 week) after the
      End-of-Last-Cycle Visit (or Early Exit Visit) for final safety assessments.Objective response
      rate is the primary end point for this study. Response evaluation will be performed using the
      International Working Group (IWG) revised response criteria for malignant lymphoma.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated based on interim results and all subjects were off study at that time.
    No major safety or tolerability concerns
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Overall Objective Response Rate</measure>
    <time_frame>End of every 2 cycles and end of the study treatment</time_frame>
    <description>The primary efficacy endpoint is the proportion of subjects achieving an objective response. The proportion of patients achieving an objective response is the best overall objective response rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>End of the study treatment</time_frame>
    <description>It is defined as the time from when the measurement criteria are met for complete or partial response until the first date that recurrent or progressive disease is objectively or clinically documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>End of study treatment</time_frame>
    <description>It is defined as the time from day 1 of the study drug administration until the first date of progressive disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>P276-00</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P276-00</intervention_name>
    <description>P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity</description>
    <arm_group_label>P276-00</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Histological diagnosis of MCL and presence of either nuclear Cyclin D1 positivity by
             immunohistochemistry or t(11;14) by fluorescence in situ hybridization (FISH),
             polymerase chain reaction (PCR), or conventional karyotyping

          -  Documented progression or relapse after at least 1 line of prior chemotherapy

          -  Presence of measurable disease

          -  ECOG performance status 0, 1, or 2

          -  Life expectancy of at least 3 months

          -  Ability to understand and the willingness to sign a written informed consent document
             (ICD)

          -  Full recovery from all prior treatment toxicities of Common Terminology Criteria for
             Adverse Events (CTCAE) Grade ≤ 1

        Exclusion Criteria:

          -  Prior radiation therapy, chemotherapy or biologic/targeted anticancer agents within 4
             weeks of study drug administration

          -  Prior treatment with monoclonal antibodies or any radio- or toxin- immunoconjugates
             within 3 months of study drug administration; however, a patient who has had rituximab
             treatment within 3 months and has had PD after such treatment is allowed in the study.

          -  Prior allogeneic stem cell transplantation within 1 year of study drug administration

          -  Current or prior CNS lymphoma

          -  QTc &gt; 450 msec

          -  Unstable angina, myocardial infarction, CHF or stroke within previous 6 months of
             study drug administration

          -  Presence of active and serious comorbidity and uncontrolled illness other than MCL

          -  History of other prior malignancies except for properly treated basal cell or squamous
             cell carcinoma of skin, in situ cervical cancer, in situ breast cancer or early stage
             prostate cancer

          -  Hemoglobin &lt;8.0 gm/dL

          -  Absolute neutrophil count &lt;1000/mm3

          -  Platelet count &lt;50,000/mm3

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &gt;3 × institutional
             upper limit of normal (ULN) (&gt; 5 × institutional ULN if liver is involved with
             lymphoma or if patient has Gilbert's Disease)

          -  Total bilirubin, &gt;1.5 × institutional ULN (&gt; 3 × institutional ULN if liver is
             involved with lymphoma or if patient has Gilbert's Disease)

          -  Serum creatinine &gt;1.5 × institutional ULN

          -  Patients known to be suffering from infection with human immunodeficiency virus (HIV),
             tuberculosis, Hepatitis C or Hepatitis B

          -  Pregnant or lactating women

          -  Women of childbearing potential or men not willing to use at least 2 approved methods
             of contraception (one of which being a barrier method) after signing the ICD, during
             the entire study and for at least 4 weeks following withdrawal from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brad Kahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of the Lymphoma Service and Associate Professor of Medicine, University of Wisconsin- Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabrail Nashat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEO, President, Gabrail Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martha Glenn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Medicine, Huntsman Cancer Institute, Salt Lake City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andre Goy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Lymphoma and Deputy Director of Cancer Center, Hackensack University Medical Center, Hackensack</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Lyons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>President, Cancer Care Centers of South Texas , San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nishitha Reddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center, Nashville</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reena Nair, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor and Medical Oncologist, Tata Memorial Hospital, Mumbai, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anand Pathak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Oncologist, Cancer Care Clinic and Hospital, Nagpur, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinod Raina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head Dept of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>N K Warrier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Consultant Oncologist, Malabar Institute of Medical Sciences, Calicut, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cecil Ross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant Oncologist, St. Johns Medical College &amp; Hospital, Bangalore, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kirushna kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant Oncologist, Meenakshi mission hospital and research centre, Madurai, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S H Advani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant Oncologist, Jaslok Hospital and Research Centre, Mumbai, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Johnston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Medicine, College of Medicine, Mayo Clinic, Rochester, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ajay Gopal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Medicine, Department of Medicine, University of Washington, Seattle, Washington.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig Reeder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>College of Medicine, Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Dover</city>
        <state>Ohio</state>
        <zip>44622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-5505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute, 2000 Circle of Hope, Room 2145</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Hematology/Oncology, University of Wisconsin- Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-5156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Rotary Cancer Hospital, All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>10029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johns Medical College &amp; Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>34</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malabar Institute of Medical Sciences</name>
      <address>
        <city>Calicut</city>
        <state>Kerala</state>
        <zip>16</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jaslok Hospital and Research Centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Clinic and Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meenakshi mission hospital and research centre</name>
      <address>
        <city>Madurai</city>
        <state>Tamil nadu</state>
        <zip>625107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
  </removed_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>February 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2009</study_first_posted>
  <results_first_submitted>February 29, 2012</results_first_submitted>
  <results_first_submitted_qc>June 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 27, 2012</results_first_posted>
  <last_update_submitted>June 20, 2012</last_update_submitted>
  <last_update_submitted_qc>June 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD inhibitor</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted across multiple centers in the United States and India.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>P276-00</title>
          <description>P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>P276-00</title>
          <description>P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.8" spread="9.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best Overall Objective Response Rate</title>
        <description>The primary efficacy endpoint is the proportion of subjects achieving an objective response. The proportion of patients achieving an objective response is the best overall objective response rate.</description>
        <time_frame>End of every 2 cycles and end of the study treatment</time_frame>
        <population>The efficacy population includes all patients who have completed at least two cycles of P276-00 therapy and have tumor measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>P276-00</title>
            <description>P276-00: All patients received P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there was progression of disease or unacceptable toxicity</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Objective Response Rate</title>
          <description>The primary efficacy endpoint is the proportion of subjects achieving an objective response. The proportion of patients achieving an objective response is the best overall objective response rate.</description>
          <population>The efficacy population includes all patients who have completed at least two cycles of P276-00 therapy and have tumor measurements.</population>
          <units>proportion of participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>It is defined as the time from when the measurement criteria are met for complete or partial response until the first date that recurrent or progressive disease is objectively or clinically documented.</description>
        <time_frame>End of the study treatment</time_frame>
        <population>The efficacy population includes all patients who have completed at least two cycles of P276-00 therapy and have tumor measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>P276-00</title>
            <description>P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>It is defined as the time from when the measurement criteria are met for complete or partial response until the first date that recurrent or progressive disease is objectively or clinically documented.</description>
          <population>The efficacy population includes all patients who have completed at least two cycles of P276-00 therapy and have tumor measurements.</population>
          <units>proportion of participants</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>It is defined as the time from day 1 of the study drug administration until the first date of progressive disease.</description>
        <time_frame>End of study treatment</time_frame>
        <population>The efficacy population includes all patients who have completed at least two cycles of P276-00 therapy and have tumor measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>P276-00</title>
            <description>P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>It is defined as the time from day 1 of the study drug administration until the first date of progressive disease.</description>
          <population>The efficacy population includes all patients who have completed at least two cycles of P276-00 therapy and have tumor measurements.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>P276-00</title>
          <description>P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 11.0">Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine,</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Left atrial dilatation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Decrreased Appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>nocturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Penile swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash Pruritic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>skin burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>spleen palpable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Post operative wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>lymphocyte count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hypophosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urticaria papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The Sponsor has terminated the study based on interim results. All subjects were off study at the time of termination. There are no major safety or tolerability concerns from this study. The study results published here are preliminary results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Alan Hatfield</name_or_title>
      <organization>Piramal Healthcare Limited</organization>
      <phone>02230275000 ext 5002</phone>
      <email>alan.hatfield@piramal.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

